Agios Pharmaceuticals (AGIO) Q4 2025 earnings summary

Executive summary

• Achieved strong commercial execution in Q4 and FY 2025, with significant revenue growth and successful launches in rare hematology, including FDA approval and US launch of ACTIVASE/AQVESME (mitapivat) for thalassemia.

• PYRUKYND delivered $20M in Q4 and $54M for full-year 2025, reflecting robust year-over-year growth and strong US demand.

• Advanced pipeline with key milestones: completed Phase 2 tebapivat trial enrollment in sickle cell disease, pre-sNDA meeting for mitapivat in sickle cell disease scheduled, and early-stage pipeline progress expected in 2026.

• Maintained robust financial discipline, ending 2025 with $1.2B in cash, supporting flexibility for launches and pipeline advancement.

Financial highlights

• Q4 PYRUKYND revenue was $20M, up 86% year-over-year and 55% sequentially; FY 2025 net revenues were $54M, up 48% from FY 2024.

• US Q4 PYRUKYND revenue reached $16M, driven by PK deficiency demand and favorable adjustments; ex-US Q4 revenue was $4M, mainly from inventory stocking in Europe.

• Q4 cost of sales: $1.9M; R&D expenses: $88.1M (up $5.3M YoY); SG&A: $51.6M (flat YoY).

• FY 2025 net loss was $(412.8)M, compared to net income of $673.7M in FY 2024, which included significant one-time gains.

• Cash, cash equivalents, and marketable securities at year-end: $1.2B.

Outlook and guidance

• 2026 US PK deficiency revenues expected in the $45–$50M range.

• Operating expenses in 2026 anticipated to be roughly flat with 2025, with investments focused on ACTIVASE/AQVESME launch and pipeline.

• Clear path to profitability through commercial presence in thalassemia and PK deficiency, with disciplined capital allocation.

• Anticipate strong catalyst flow in 2026, including regulatory milestones and topline data readouts for multiple pipeline assets.

• Ex-US revenues expected to decline sequentially in Q1 2026 due to inventory dynamics.